IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive: As proof of principle, we previously reported the case of a b2a2 CP-CML patient, in CCyR and DMR after IFN-α only, who incurred an increasing molecular relapse (with rapid loss of MMR) 2 years after interferon discontinuation.